Pharmaceutical R&D efficiency - a fleeting imperative
R&D efficiency – though remaining quite difficult to measure in ‘productive’ terms – is fast becoming a key differentiating factor between pharmaceutical companies
Health Care
Consumer products, a great game between pharma majors
Glaxo Smith Kline, just a few days after withdrawing as a potential buyer of the consumer health division Pfizer intends to auction, bought out the minority stake held by Novartis in their consumer healthcare joint venture